Correvio Pharma Corp. Research and Development Expense (Excluding Acquired in Process Cost)
Correvio Pharma Corp. reported Research and Development Expense (Excluding Acquired in Process Cost) of $0 for the 12-month period ending 2017-12-31, per its 20-F filed 2018-04-30.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost · last filed 2018-04-30
| Period end | Research and Development Expense (Excluding Acquired in Process Cost) 12 month |
|---|---|
| 2017-12-31 | $0.00 20-F · filed 2018-04-30 |
| 2016-12-31 | $0.00 20-F · filed 2018-04-30 |
| 2015-12-31 | $3.22M 20-F · filed 2018-04-30 |
| 2014-12-31 | $637.00K 40-F · filed 2016-03-29 |
| 2013-12-31 | $476.00K 40-F · filed 2015-03-27 |
| 2012-12-31 | $6.02M 40-F/A · filed 2014-04-30 |
| 2011-12-31 | $15.22M 20-F/A · filed 2013-04-18 |
| 2010-12-31 | $15.34M 20-F/A · filed 2013-04-18 |